Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Apr 2, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on developing new treatments for infections caused by a type of bacteria called Pseudomonas aeruginosa. This bacteria is known to cause serious infections, especially in hospitals, and can sometimes resist many antibiotics, making it difficult to treat. The study aims to isolate and create special proteins called antibodies that can help fight against this bacteria, offering a potential alternative to traditional antibiotic treatments for patients who have infections with antibiotic-resistant strains.

To participate in this trial, you need to be between 65 and 74 years old and weigh at least 32 kilograms. You should also have had a follow-up visit at Grenoble University Hospital where a blood sample was taken, and you must agree to take part in the study. Participants will be helping researchers understand how effective these antibodies can be in treating infections, and you will be closely monitored throughout the trial. It's important to note that individuals who are minors, pregnant, nursing, or legally protected cannot participate in this study. This trial represents a hopeful step in finding new solutions for tough-to-treat infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
• • Patient with weight ≥ 32kg.
• • With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
• • Having given its written no objection to participate in the prospective phase of this project
• Exclusion Criteria:
• • Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)